Literature DB >> 14704859

The Ets-1 transcription factor is involved in the development and invasion of malignant melanoma.

T Rothhammer1, J C Hahne, A Florin, I Poser, F Soncin, N Wernert, A-K Bosserhoff.   

Abstract

The Ets-1 transcription factor plays a role in tumor vascularization and invasion by regulating expression of matrix-degrading proteases in endothelial cells and fibroblasts in the tumor stroma. During early embryogenesis, Ets-1 is expressed in migrating neural crest cells from which melanocytes arise. In the present study, we analyzed Ets-1 expression in various melanocytic lesions and investigated its functional importance in malignant melanomas. We found that Ets-1 was upregulated both in vivo and in vitro in malignant melanoma, compared to benign melanocytic lesions and to primary melanocytes. Assessment of DNA-binding and transactivation assays documented a strong Ets activity in melanoma cells. Using an antisense strategy, the expression and activity of Ets-1 were reduced in the melanoma cell line Mel Im. This correlated with a diminished expression of several Ets-1 target genes known to be involved in invasion, such as MMP1, MMP3, uPA and integrin beta3. In line with these findings, the invasive potential of the melanoma cells measured in a Boyden Chamber model was reduced up to 60% after Ets-1 blockade. This can be attributed to the role of Ets-1 in transcriptional regulation of factors involved in invasion of melanoma cells. We conclude that over-expression of Ets-1 during melanoma development contributes to the malignant phenotype.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14704859     DOI: 10.1007/s00018-003-3337-8

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  55 in total

1.  The prevention of heart failure--a new agenda.

Authors:  J N Cohn
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

3.  Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure.

Authors:  George G Sokos; Lazaros A Nikolaidis; Sunil Mankad; Dariush Elahi; Richard P Shannon
Journal:  J Card Fail       Date:  2006-12       Impact factor: 5.712

4.  Efficacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF.

Authors:  Prakash C Deedwania; Thomas D Giles; Michael Klibaner; Jalal K Ghali; Johan Herlitz; Per Hildebrandt; John Kjekshus; Jindrich Spinar; Jiri Vitovec; Hilary Stanbrook; John Wikstrand
Journal:  Am Heart J       Date:  2005-01       Impact factor: 4.749

5.  Glycemic control and heart failure among adult patients with diabetes.

Authors:  C Iribarren; A J Karter; A S Go; A Ferrara; J Y Liu; S Sidney; J V Selby
Journal:  Circulation       Date:  2001-06-05       Impact factor: 29.690

6.  Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.

Authors:  Albert A Carr; Peter R Kowey; Richard B Devereux; Barry M Brenner; Björn Dahlöf; Hans Ibsen; Lars H Lindholm; Paulette A Lyle; Steven M Snapinn; Zhongxin Zhang; Jonathan M Edelman; Shahnaz Shahinfar
Journal:  Am J Cardiol       Date:  2005-10-17       Impact factor: 2.778

7.  Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project.

Authors:  Silvio E Inzucchi; Frederick A Masoudi; Yongfei Wang; Mikhail Kosiborod; Joanne M Foody; John F Setaro; Edward P Havranek; Harlan M Krumholz
Journal:  Diabetes Care       Date:  2005-07       Impact factor: 19.112

8.  Insulin resistance and risk of congestive heart failure.

Authors:  Erik Ingelsson; Johan Sundström; Johan Arnlöv; Björn Zethelius; Lars Lind
Journal:  JAMA       Date:  2005-07-20       Impact factor: 56.272

9.  Usefulness of aminoterminal pro-brain natriuretic peptide testing for the diagnostic and prognostic evaluation of dyspneic patients with diabetes mellitus seen in the emergency department (from the PRIDE Study).

Authors:  Michelle O'Donoghue; Patrick Kenney; Eveline Oestreicher; Saif Anwaruddin; Aaron L Baggish; Daniel G Krauser; Annabel Chen; Roderick Tung; Renee Cameron; James L Januzzi
Journal:  Am J Cardiol       Date:  2007-08-09       Impact factor: 2.778

10.  GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice.

Authors:  Mohammad Hossein Noyan-Ashraf; M Abdul Momen; Kiwon Ban; Al-Muktafi Sadi; Yu-Qing Zhou; Ali M Riazi; Laurie L Baggio; R Mark Henkelman; Mansoor Husain; Daniel J Drucker
Journal:  Diabetes       Date:  2009-01-16       Impact factor: 9.461

View more
  36 in total

1.  Regulation of the transcription factor Ets-1 by DNA-mediated homo-dimerization.

Authors:  Ekaterina P Lamber; Laurent Vanhille; Larissa C Textor; Galina S Kachalova; Michael H Sieweke; Matthias Wilmanns
Journal:  EMBO J       Date:  2008-06-19       Impact factor: 11.598

2.  Aberrant expression of c-Jun in glioblastoma by internal ribosome entry site (IRES)-mediated translational activation.

Authors:  Lior Blau; Revital Knirsh; Iris Ben-Dror; Sivan Oren; Silke Kuphal; Peter Hau; Martin Proescholdt; Anja-Katrin Bosserhoff; Lily Vardimon
Journal:  Proc Natl Acad Sci U S A       Date:  2012-10-01       Impact factor: 11.205

3.  MicroRNA miR-196a is a central regulator of HOX-B7 and BMP4 expression in malignant melanoma.

Authors:  Simone Braig; Daniel W Mueller; Tanja Rothhammer; Anja-Katrin Bosserhoff
Journal:  Cell Mol Life Sci       Date:  2010-05-18       Impact factor: 9.261

4.  Neuregulin-1 is a chemoattractant and chemokinetic molecule for trunk neural crest cells.

Authors:  Maria Elena De Bellard; Blanca Ortega; Sothy Sao; Lino Kim; Joshua Herman; Nora Zuhdi
Journal:  Dev Dyn       Date:  2018-03-25       Impact factor: 3.780

Review 5.  Histamine receptors and cancer pharmacology: an update.

Authors:  Noelia A Massari; Melisa B Nicoud; Vanina A Medina
Journal:  Br J Pharmacol       Date:  2018-12-13       Impact factor: 8.739

6.  The transcription factors Ets1 and Sox10 interact during murine melanocyte development.

Authors:  Amy Saldana-Caboverde; Erasmo M Perera; Dawn E Watkins-Chow; Nancy F Hansen; Meghana Vemulapalli; James C Mullikin; William J Pavan; Lidia Kos
Journal:  Dev Biol       Date:  2015-04-23       Impact factor: 3.582

7.  Ets-1 regulates energy metabolism in cancer cells.

Authors:  Meghan L Verschoor; Leigh A Wilson; Chris P Verschoor; Gurmit Singh
Journal:  PLoS One       Date:  2010-10-22       Impact factor: 3.240

8.  Acacetin, a flavonoid, inhibits the invasion and migration of human prostate cancer DU145 cells via inactivation of the p38 MAPK signaling pathway.

Authors:  Kun-Hung Shen; Shun-Hsing Hung; Li-Te Yin; Chun-Shui Huang; Chang-Hung Chao; Chein-Liang Liu; Yuan-Wei Shih
Journal:  Mol Cell Biochem       Date:  2009-08-20       Impact factor: 3.396

9.  An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.

Authors:  Laetitia Seguin; Shumei Kato; Aleksandra Franovic; M Fernanda Camargo; Jacqueline Lesperance; Kathryn C Elliott; Mayra Yebra; Ainhoa Mielgo; Andrew M Lowy; Hatim Husain; Tina Cascone; Lixia Diao; Jing Wang; Ignacio I Wistuba; John V Heymach; Scott M Lippman; Jay S Desgrosellier; Sudarshan Anand; Sara M Weis; David A Cheresh
Journal:  Nat Cell Biol       Date:  2014-04-20       Impact factor: 28.824

10.  Antimetastatic potential of fisetin involves inactivation of the PI3K/Akt and JNK signaling pathways with downregulation of MMP-2/9 expressions in prostate cancer PC-3 cells.

Authors:  Chi-Sheng Chien; Kun-Hung Shen; Jau-Shyang Huang; Shian-Chin Ko; Yuan-Wei Shih
Journal:  Mol Cell Biochem       Date:  2009-07-26       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.